The U.S. Food and Drug Administration today is requiring safety labeling changes for a class of antibiotics called fluoroquinolones to strengthen the warnings about the risks of mental health side effects...

Melinta Therapeutics, Inc. , a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the U.S. launch of intravenous and oral formulations...

The Food and Drug Administration recently approved a new antibiotic into the arsenal for treating serious acute bacterial skin and skin structure infections (ABSSSI). Its called delafloxacin and goes by...

Melinta Therapeutics announced Monday that the U.S. Food and Drug Administration (FDA) has approved Baxdela™ (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure...

Melinta Therapeutics announced Monday that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for approval of IV and oral Baxdela™ (delafloxacin) for the treatment...

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced last week top-line results from the second Phase 3 study (RX-3341-303 NCT01984684)...